Pancreatic Carcinoma Stage I Clinical Trial
Official title:
A Phase 2 Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein [Mucin 1-Glutathione S-Transferase] Coupled to Oxidized Polymannose) in Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas
| Verified date | March 2015 |
| Source | Prima BioMed Ltd |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Bulgaria: Bulgarian Drug Agency |
| Study type | Interventional |
The purpose of this study is to assess the safety and tolerability of CVac, an
investigational cell therapy, in patients with resected stage I or II adenocarcinoma of the
pancreas who have completed surgery with or without front-line chemotherapy or radiation
therapy.
After confirmation of non-measurable disease patients will undergo leukapheresis for
manufacture of the study agent.
| Status | Withdrawn |
| Enrollment | 0 |
| Est. completion date | March 2015 |
| Est. primary completion date | March 2015 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: 1. Histologically or cytologically diagnosed adenocarcinoma of the pancreas, stage I or stage II disease 2. Postoperative confirmed R0 or R1 resection status with no evidence of residual disease based on radiographic Imaging 3. CA 19-9 less than 2 × the ULN by the central laboratory 4. No greater than 6 weeks since completion of prior therapy, which includes surgery with or without radiation or chemotherapy 5. Mucin 1-positive tumor as determined by central immunohistopathology. Sites will be asked to submit archival tissue (patients may start the study if tissue is available at an outside hospital, but not yet requested or received) 6. Signed an informed consent form (ICF) 7. Willing and able to complete study procedures within the study timelines 8. Life expectancy of at least 6 months in the investigator's opinion 9. = 18 years of Age 10. ECOG performance status < 2 (Karnofsky = 70%) 11. Normal organ and marrow function: serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3 × ULN and serum bilirubin = 1.5 × ULN unless Gilbert's syndrome has previously been confirmed for the patient, white blood cells (WBCs) = 3.0 K/µL, absolute neutrophil count (ANC) = 1.0 × 109/L, hemoglobin = 8 g/dL, and platelets = 100 × 109/L 12. Not pregnant, and if of childbearing potential, agrees to use a highly effective method of birth control (implanted, injectable, or oral combination hormonal method alone or in possible combinations, intrauterine device, vasectomized partner, or abstinence) prior to study entry, for the duration of the study, and for 3 months after the last dose of Cvac. Male partners of a study patient must use a condom in addition to the acceptable method of contraception for the female partner as specified above Exclusion Criteria: 1. Active, acute, or chronic clinically significant infections or bleeding 2. Uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg) or history of congestive heart failure (= Grade 2) 3. Active angina pectoris, stroke, or recent myocardial infarction (within 6 months) 4. Additional uncontrolled, serious medical or psychiatric illness 5. Evidence or history of central nervous system metastases 6. Inadequate renal function defined as a creatinine clearance < 60 mL/min as determined by the central laboratory 7. Additional malignancy diagnosed within 5 years of study enrollment, except carcinoma in situ of the cervix or basal cell and squamous cell carcinomas of the skin 8. Treatment with any other investigational agent (for any condition) within 4 weeks of Screening 9. Infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or syphilis (Treponema pallidum [TPHA]) 10. Concurrent systemic treatment with steroids or other immunosuppressant agents at a dose considered by the investigator to be higher than a standard physiological dose 11. Active autoimmune disease; any previous autoimmune disease must not require chronic treatment in the 6 months prior to screening 12. Germany only: Oversensitivity to the substances or another component of the investigational medicinal product |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Prima BioMed Ltd |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Evaluation of the time to next treatment (TTNT) | Baseline until end of Progression free survival for up to 36 months | No | |
| Other | Evaluation of the immunologic response to Cvac administration in this patient population | Descriptive statistics will be used to summarize the changes in immunologic Response. | Baseline until end of Progression free survival for up to 36 months | No |
| Other | Investigation of biomarkers, including tumor and immune characteristics, of clinical efficacy of Cvac in this patient population | Immunologic parameters will be evaluated as exploratory efficacy endpoints. Plasma, serum, and tissue (i.e., tumor sample collected during surgery) samples will be collected and will be used for immunological assays. | Baseline until end of Progression free survival for up to 36 months | No |
| Other | Assessment of the change in quality of life (QoL) following the initiation of Cvac in this patient population | Quality-of-life scores will be calculated based on the QLQ-C30 and Module QLQ-PAN26 scoring manuals. The QoL scores will be summarized. descriptively. Data permitting, the QoL scores may be evaluated longitudinally using a linear mixed-effects model for repeated measurements. | Baseline until end of Progression free survival for up to 36 months | No |
| Primary | Assessment of safety and tolerability of CVac. (adverse events, vital signs, 12 lead ECG, relevant changes in physical examination) | Safety analyses will be performed on the Safety Population. Safety and tolerability will be summarized using descriptive statistics and or listed and assessed by adverse events, vital signs, 12 lead ECG, relevant changes in physical examination. | 10-12 months | Yes |
| Secondary | Assessment of Progression-Free Survival (PFS) and Overall Survival (OS) following the initiation of Cvac in this patient population | The efficacy endpoints for this pilot study include OS and PFS, PFS is defined as the time from baseline to the date of radiological scan used to determine Progressive disease evaluated approximately every 12 weeks after baseline. | Participants will be followed from baseline until death from any cause or end of study, whichever comes first, assessed approximately every 12 weeks for up to 36 month | No |